A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

NCT04177290 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced or Metastatic NSCLC

Interventions

DRUG: Sintilimab (M1b)
DRUG: Sintilimab (approved)

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.